Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1658
This examiner grants 30% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19440230 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | Final Rejection | Entera Bio Ltd. |
| 19378410 | SEMAGLUTIDE IN THE TREATMENT OF PERIPHERAL ARTERIAL DISEASE | Final Rejection | Novo Nordisk A/S |
| 19407885 | Interleukin-15, PD-1 Antibodies, and Taxanes in Non-Small Cell Lung Cancer | Final Rejection | ImmunityBio, Inc. |
| 17785561 | STRUCTURALLY-STABILIZED ONCOLYTIC PEPTIDES AND USES THEREOF | Non-Final OA | Dana-Farber Cancer Institute, Inc. |
| 18249858 | FUSION PROTEIN TARGETING MITOCHONDRIA, METHOD OF MAKING AND USE THEREOF | Non-Final OA | UNIVERSITY OF ROCHESTER |
| 18258720 | PESTICIDAL HEXATOXIN POLYPEPTIDES AND METHODS OF USE THEREOF | Non-Final OA | SYNGENTA CROP PROTECTION AG |
| 18339230 | COMPOSITIONS FOR CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY AND USES THEREOF | Final Rejection | Massachusetts Institute of Technology |
| 18020082 | PEPTIDE SELECTIVELY BINDING TO CANCER CELL-DERIVED EXOSOME, AND USES THEREOF | Non-Final OA | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy